# A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease

> **NCT07677358** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 28 (estimated)

## Conditions studied

- Hepatic Impairment
- Healthy, Hepatic Insufficiency
- Healthy Adults

## Interventions

- **DRUG:** Atirmociclib

## Key facts

- **NCT ID:** NCT07677358
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-29
- **Primary completion:** 2027-08-14
- **Final completion:** 2027-09-10
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677358, "A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07677358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*